FDA Approves Zegfrovy for EGFR Exon 20 Insertion Mutation in Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has granted approval for Zegfrovy, a treatment developed by Dizal Pharmaceutical, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR exon 20 insertion mutations. The decision marks a significant regulatory milestone for the therapy, which targets a specific subset of NSCLC cases.

Zegfrovy’s approval applies to patients whose cancer exhibits the rare EGFR exon 20 insertion mutation, a genetic alteration that is often associated with resistance to standard treatments. This development follows clinical evaluations demonstrating the drug’s efficacy and safety in addressing this challenging form of lung cancer. The FDA’s decision provides an additional therapeutic option for individuals diagnosed with this condition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 3, 2025

Related posts:

Pharmaceutical Companies Extend Drug Patents Using Method-of-Use Strategies Post-ANDA. New Mask Detects Chronic Kidney Disease in 84% of Tested Cases MHRA Issues First Guidance on Phage-Based Medicinal Products in the UK Avenzo Therapeutics Begins Phase I/II Trial for CDK4-Selective Breast Cancer Drug Amid MCRC Partnerships to Expedite Clinical Site Activation

Author

Mark Chiang